Business Context and Reporting Period
This Form 8-K Current Report was filed by Abbott Laboratories on December 9, 2011. The report details corporate governance changes, specifically the election of new directors and an amendment to the company's by-laws regarding board size.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and does not contain financial performance data.
Material Changes
- Board Composition: The Board of Directors was expanded from ten to twelve persons, effective December 9, 2011.
- New Directors: Sally E. Blount, Ph.D., and Nancy McKinstry were named to the Board of Directors, effective immediately.
- By-Law Amendment: Article III, Section 2 of the by-laws was amended to reflect the new board size.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for financial guidance, outlook, management commentary on operations, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the professional backgrounds of new directors Sally E. Blount and Nancy McKinstry.
- Confirm the effective date of the by-law amendment regarding the twelve-person board limit.
- Review the full text of the amended By-Laws (Exhibit 3.1) for any other governance changes.